Contact us

Please complete the form below and a member of the AQUIPTA^®▼ (atogepant) team will get back to you.

Please fill in your details below only if you are a UK registered healthcare professional and would like to contact an AbbVie representative.

AQUIPTA^® is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.¹

The AQUIPTA^® prescribing information and adverse event reporting information can be found at the bottom of the page.

First name:*

Please enter First name

Last name:*

Please enter Last name

Role:*

Please enter Role

E-mail address:*

E-mail address is not valid

Phone number:

Please enter Last name

Hospital name:

Please enter Hospital name

Hospital postcode:

Please enter hospital postcode

Areas of interest

Please select the items you are interested in:

Please note that there may be certain circumstances where we contact you in relation to important AbbVie product or information which we are required to provide to you or your patients as a matter of law, or in order to comply with the obligations we owe to you or them. This type of communications does not constitute as promotional communication.

You can withdraw your consent at any time by using the unsubscribe option in the email or contacting privacyoffice@abbvie.com. For further information about AbbVie’s privacy practices, please refer to the AbbVie Privacy notice.

Request a meeting with your local AbbVie Account Specialist

Please select a field.

I consent to receive AbbVie Ltd. communications about its products, services, research, events, programmes and other information, including promotional content, that may be of interest to me, using the information I provide. I may withdraw my consent at any time.

Please select one field.

Please refer to the AbbVie privacy notice here for more information on how AbbVie processes your personal data and your data privacy rights.

*Denotes mandatory field

Incorrect. Please try again.

References:

1. AQUIPTA^® Summary of Product Characteristics.

References:

1. AQUIPTA^® Summary of Product Characteristics.

Please refer to the AQUIPTA^® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use. The AQUIPTA^® Summary of Product Characteristics can be found here.

AQUIPTA® PRESCRIBING INFORMATION

By clicking the link above you will leave the AbbVie Pro website and be taken to the eMC PI portal website.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk

Adverse events should also be reported to AbbVie on GBPV@abbvie.com

UK-AQP-250082. Date of preparation: March 2025.

Contact us

Our therapy areas

Additional info

This website is for UK Healthcare Professionals only

Welcome